Epstein-Barr Virus-Related Post-Transplantation Lymphoproliferative Disorder after Unmanipulated Human Leukocyte Antigen Haploidentical Hematopoietic Stem Cell Transplantation: Incidence, Risk Factors, Treatment, and Clinical Outcomes

Biology of Blood and Marrow Transplantation

Volumn 21, Issue 12, 2015, Pages 2185-2191

  Xu, Lan Ping ^a   Zhang, Chun Li ^b   Mo, Xiao Dong ^a   Zhang, Xiao Hui ^a   Chen, Huan ^a   Han, Wei ^a   Chen, Yu Hong ^a   Wang, Yu ^a   Yan, Chen Hua ^a   Wang, Jing Zhi ^a   Wang, Feng Rong ^a   Zhao, Ting ^a   Liu, Yan Rong ^a   Liu, Kai Yan ^a   Huang, Xiao Jun ^a,c,d  

^a PEKING UNIVERSITY PEOPLE S HOSPITAL   (China)

^b BEIJING HOSPITAL   (China)

^c Beijing Military Area Command of Chinese PLA   (China)

^d Tsinghua University   (China)

Author keywords

Epstein Barr virus related post transplantation lymphoproliferative disorder; Haploidentical; Hematopoietic stem cell transplantation; Immune reconstitution; Rituximab

Indexed keywords

BUSULFAN; CD8 ANTIGEN; CORTICOSTEROID; CYCLOPHOSPHAMIDE; CYTARABINE; HLA ANTIGEN; IMMUNOGLOBULIN M; RITUXIMAB; SEMUSTINE; THYMOCYTE ANTIBODY; VIRUS DNA; IMMUNOSUPPRESSIVE AGENT;

ADOLESCENT; ADULT; ARTICLE; CD8+ T LYMPHOCYTE; CHILD; CLINICAL ARTICLE; COHORT ANALYSIS; CONTROLLED STUDY; CYTOMEGALOVIRUS; EPSTEIN BARR VIRUS; FEMALE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HIGH RISK PATIENT; HUMAN; INCIDENCE; MALE; NONHUMAN; OVERALL SURVIVAL; POSTTRANSPLANT LYMPHOPROLIFERATIVE DISEASE; RISK FACTOR; TREATMENT OUTCOME; VIREMIA; ALLOTRANSPLANTATION; BLOOD; EPSTEIN-BARR VIRUS INFECTIONS; GENETICS; HAPLOTYPE; HEMATOLOGIC NEOPLASMS; HISTOCOMPATIBILITY TEST; IMMUNOLOGY; ISOLATION AND PURIFICATION; MIDDLE AGED; MORTALITY; PATHOGENICITY; PATHOLOGY; PRESCHOOL CHILD; PROCEDURES; RETROSPECTIVE STUDY; SURVIVAL ANALYSIS; VIROLOGY;

ADOLESCENT; ADULT; CD8-POSITIVE T-LYMPHOCYTES; CHILD; CHILD, PRESCHOOL; CYTOMEGALOVIRUS; DNA, VIRAL; EPSTEIN-BARR VIRUS INFECTIONS; FEMALE; HAPLOTYPES; HEMATOLOGIC NEOPLASMS; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HERPESVIRUS 4, HUMAN; HISTOCOMPATIBILITY TESTING; HUMANS; IMMUNOGLOBULIN M; IMMUNOSUPPRESSIVE AGENTS; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; RISK FACTORS; RITUXIMAB; SURVIVAL ANALYSIS; TRANSPLANTATION, HOMOLOGOUS; TREATMENT OUTCOME;

EID: 84947490067     PISSN: 10838791     EISSN: 15236536     Source Type: Journal    
DOI: 10.1016/j.bbmt.2015.07.035     Document Type: Article

References (36)

1. Gottschalk S., Rooney C.M., Heslop H.E. Post-transplant lymphoproliferative disorders. Annu Rev Med 2005, 56:29-44.
2. Loren A.W., Porter D.L., Stadtmauer E.A., Tsai D.E. Posttransplant lymphoproliferative disorder: a review. Bone Marrow Transplant 2003, 31:145-155.
3. Baker K.S., DeFor T.E., Burns L.J., et al. New malignancies after blood or marrow stem-cell transplantation in children and adults: incidence and risk factors. J Clin Oncol 2003, 21:1352-1358.
4. Uhlin M., Wikell H., Sundin M., et al. Risk factors for Epstein-Barr virus-related post-transplant lymphoproliferative disease after allogeneic hematopoietic stem cell transplantation. Haematologica 2014, 99:346-352.
5. Styczynski J., Gil L., Tridello G., et al. Response to rituximab-based therapy and risk factor analysis in Epstein Barr Virus-related lymphoproliferative disorder after hematopoietic stem cell transplant in children and adults: a study from the Infectious Diseases Working Party of the European Group for Blood and Marrow Transplantation. Clin Infect Dis 2013, 57:794-802.
6. Bower M. The management of lymphoma in the immunosuppressed patient. Best Pract Res Clin Haematol 2002, 15:517-532.
7. Reddy N., Rezvani K., Barrett A.J., Savani B.N. Strategies to prevent EBV reactivation and posttransplant lymphoproliferative disorders (PTLD) after allogeneic stem cell transplantation in high-risk patients. Biol Blood Marrow Transplant 2011, 17:591-597.
8. van Esser J.W., Niesters H.G., van der Holt B., et al. Prevention of Epstein-Barr virus-lymphoproliferative disease by molecular monitoring and preemptive rituximab in high-risk patients after allogeneic stem cell transplantation. Blood 2002, 99:4364-4369.
9. Walker R.C., Marshall W.F., Strickler J.G., et al. Pretransplantation assessment of the risk of lymphoproliferative disorder. Clin Infect Dis 1995, 20:1346-1353.
10. Allen U.D., Farkas G., Hébert D., et al. Risk factors for post-transplant lymphoproliferative disorder in pediatric patients: a case-control study. Pediatr Transplant 2005, 9:450-455.
11. Sundin M., Le Blanc K., Ringdén O., et al. The role of HLA mismatch, splenectomy and recipient Epstein-Barr virus seronegativity as risk factors in post-transplant lymphoproliferative disorder following allogeneic hematopoietic stem cell transplantation. Haematologica 2006, 91:1059-1067.
12. Curtis R.E., Travis L.B., Rowlings P.A., et al. Risk of lymphoproliferative disorders after bone marrow transplantation: a multi-institutional study. Blood 1999, 94:2208-2216.
13. Sebelin-Wulf K., Nguyen T.D., Oertel S., et al. Quantitative analysis of EBV-specific CD4/CD8 T cell numbers, absolute CD4/CD8 T cell numbers and EBV load in solid organ transplant recipients with PLTD. Transpl Immunol 2007, 17:203-210.
14. Pearce N. What does the odds ratio estimate in a case-control study?. Int J Epidemiol 1993, 22:1189-1192.
15. Huang X.J., Liu D.H., Liu K.Y., et al. Treatment of acute leukemia with unmanipulated HLA-mismatched/haploidentical blood and bone marrow transplantation. Biol Blood Marrow Transplant 2009, 15:257-265.
16. Liu Y., Chen S., Yu H. Standardization and quality control in flow cytometric enumeration of CD34(+) cells. Zhongguo Shi Yan Xue Ye Xue Za Zhi 2000, 8:302-306.
17. Huang X.J., Liu D.H., Liu K.Y., et al. Haploidentical hematopoietic stem cell transplantation without in vitro T cell depletion for the treatment of hematological malignancies. Bone Marrow Transplant 2006, 38:291-297.
18. Przepiorka D., Weisdorf D., Martin P., et al. 1994 Consensus Conference on Acute GVHD Grading. Bone Marrow Transplant 1995, 15:825-828.
19. Styczynski J., Reusser P., Einsele H., et al. Management of HSV, VZV and EBV infections in patients with hematological malignancies and after SCT: guidelines from the Second European Conference on Infections in Leukemia. Bone Marrow Transplant 2009, 43:757-770.
20. Styczynski J., Einsele H., Gil L., Ljungman P. Outcome of treatment of Epstein-Barr virus-related post-transplant lymphoproliferative disorder in hematopoietic stem cell recipients: a comprehensive review of reported cases. Transpl Infect Dis 2009, 11:383-392.
21. Gooley T.A., Leisenring W., Crowley J., Storer B.E. Estimation of failure probabilities in the presence of competing risks: new representations of old estimators. Stat Med 1999, 18:695-706.
22. Meij P., van Esser J.W., Niesters H.G., et al. Impaired recovery of Epstein-Barr virus (EBV)-specific CD8+ T lymphocytes after partially T-depleted allogeneic stem cell transplantation may identify patients at very high risk for progressive EBV reactivation and lymphoproliferative disease. Blood 2003, 101:4290-4297.
23. Luo X.H., Huang X.J., Li D., et al. Immune reconstitution to cytomegalovirus following partially matched-related donor transplantation: impact of in vivo T-cell depletion and granulocyte colony-stimulating factor-primed peripheral blood/bone marrow mixed grafts. Transpl Infect Dis 2013, 15:22-33.
24. Chang Y.J., Zhao X.Y., Huo M.R., et al. Immune reconstitution following unmanipulated HLA-mismatched/haploidentical transplantation compared with HLA-identical sibling transplantation. J Clin Immunol 2012, 32:268-280.
25. Zallio F., Primon V., Tamiazzo S., et al. Epstein-Barr virus reactivation in allogeneic stem cell transplantation is highly related to cytomegalovirus reactivation. Clin Transplant 2013, 27:E491-E497.
26. Battiwalla M., Wu Y., Bajwa R.P., et al. Ganciclovir inhibits lymphocyte proliferation by impairing DNA synthesis. Biol Blood Marrow Transplant 2007, 13:765-770.
27. Hale G., Waldmann H. Risks of developing Epstein-Barr virus-related lymphoproliferative disorders after T-cell-depleted marrow transplants. CAMPATH Users. Blood 1998, 91:3079-3083.
28. Kanakry J.A., Kasamon Y.L., Bolaños-Meade J., et al. Absence of post-transplantation lymphoproliferative disorder after allogeneic blood or marrow transplantation using post-transplantation cyclophosphamide as graft-versus-host disease prophylaxis. Biol Blood Marrow Transplant 2013, 19:1514-1517.
29. Tischer J., Engel N., Fritsch S., et al. Virus infection in HLA-haploidentical hematopoietic stem cell transplantation: incidence in the context of immune recovery in two different transplantation settings. Ann Hematol 2015 Jun 10, [Epub ahead of print].
30. Dharnidharka V.R., Tejani A.H., Ho P.L., Harmon W.E. Post-transplant lymphoproliferative disorder in the United States: young Caucasian males are at highest risk. Am J Transplant 2002, 2:993-998.
31. Xiong G., Zhang B., Huang M.Y., et al. Epstein-Barr virus (EBV) infection in Chinese children: a retrospective study of age-specific prevalence. PLoS One 2014, 9:e99857.
32. Zeng Y., Pi G.H., Deng H., et al. Epstein-Barr virus seroepidemiology in China. AIDS Res 1986, 2:S7-S15.
33. Liu J., Yan C., Zhang C., et al. Late-onset Epstein-Barr virus-related disease in acute leukemia patients after haploidentical hematopoietic stem cell transplantation is associated with impaired early recovery of T and B lymphocytes. Clin Transplant 2015, [Epub ahead of print]. 10.1111/ctr.12593.
34. Xu L.P., Liu D.H., Liu K.Y., et al. The efficacy and safety of donor lymphocyte infusion to treat Epstein-Barr virus associated lymphoproliferatie disease after allogeneic hematopoietic stem cell transplantation. Zhonghua Nei Ke Za Zhi 2011, 49:955-958.
35. Lucas K.G., Salzman D., Garcia A., Sun Q. Adoptive immunotherapy with allogeneic Epstein-Barr virus (EBV)-specific cytotoxic T-lymphocytes for recurrent, EBV-positive Hodgkin disease. Cancer 2004, 100:1892-1901.
36. Heslop H.E., Slobod K.S., Pule M.A., et al. Long-term outcome of EBV-specific T-cell infusions to prevent or treat EBV-related lymphoproliferative disease in transplant recipients. Blood 2010, 115:925-935.